Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

4.640 -0.070 (-1.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating RH, Alvotech, and TriplePoint and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses to Inquire About Securities Class Action Investigation - ALVO, ALVOW
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Alvotech to Participate in Jefferies Healthcare Conference
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Issues Annual Equality Report Covering 2022
From Alvotech
Via GlobeNewswire
News headline image
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
From Alvotech
Via GlobeNewswire
News headline image
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOW
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
From Alvotech
Via GlobeNewswire
News headline image
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
From Alvotech
Via GlobeNewswire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Provides Update on Corporate Sustainability Framework
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
From Alvotech
Via GlobeNewswire
News headline image
Settlement of Alvotech Private Share Placement Completed
From Alvotech
Via GlobeNewswire
News headline image
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.